#APTUS MERCHANT SERVICES TRIAL#
“I think the actual idea behind the trial is fantastic, I think it should help people.
“I said if could be of any help I’d be happy to take part,” said Mr Westworth. Mr Westworth said he is ‘fascinated by technology’, and was happy to consent to taking part in EMBRaCE when he was approached by the study team. Mr Westworth will be taking part in the trial in the next couple of weeks when he receives his first infusion of CAR-T (Chimeric Antigen Receptor T-cell) therapy – a personalised medicine used to treat patients with certain types of leukaemia and lymphoma. Now retired, he was self-employed within the building trade for 40 years, and has been receiving care for lymphoma at Manchester Royal Infirmary, part of Manchester University NHS Foundation Trust (MFT), for three months. Thomas Westworth, 70, is from South Lakeland in the Lake District. “It could even support the development of new cancer treatments by developing a digital platform for clinical trials in cancer involving wearable devices or fitness trackers.” “We will find out if 24/7 data from these wearable sensors can be used to support patient recovery and provide accurate measurement outside clinic. “It will help us to identify ways that clinical staff can individualise treatment before, during, and after therapy. “We hope that it will provide new insights into how people cope with cancer treatment and what we can do to improve their recovery.”ĭr Michael Merchant, Senior Lecturer in Proton Therapy Physics, at The University of Manchester, said: “This trial will assess if the latest wearable technology has a role in cancer care. This study uses cutting-edge technology that can monitor people during their treatment, with devices that they can wear all the time. He said: “Cancer places a huge burden on the lives of people everywhere. The technologies can assess a range of vital signs, including electrocardiogram (ECG), heart rate, temperature, physical activity levels and sleep.ĭr Anthony Wilson, Consultant in Anaesthesia and Critical Care at Manchester Royal Infirmary (MRI), part of MFT, is the clinical lead for the project.
0 kommentar(er)
